1
|
Fiévet L, Espagnolle N, Gerovska D, Bernard D, Syrykh C, Laurent C, Layrolle P, De Lima J, Justo A, Reina N, Casteilla L, Araúzo-Bravo MJ, Naji A, Pagès JC, Deschaseaux F. Single-cell RNA sequencing of human non-hematopoietic bone marrow cells reveals a unique set of inter-species conserved biomarkers for native mesenchymal stromal cells. Stem Cell Res Ther 2023; 14:229. [PMID: 37649081 PMCID: PMC10469496 DOI: 10.1186/s13287-023-03437-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 07/28/2023] [Indexed: 09/01/2023] Open
Abstract
BACKGROUND Native bone marrow (BM) mesenchymal stem/stromal cells (BM-MSCs) participate in generating and shaping the skeleton and BM throughout the lifespan. Moreover, BM-MSCs regulate hematopoiesis by contributing to the hematopoietic stem cell niche in providing critical cytokines, chemokines and extracellular matrix components. However, BM-MSCs contain a heterogeneous cell population that remains ill-defined. Although studies on the taxonomy of native BM-MSCs in mice have just started to emerge, the taxonomy of native human BM-MSCs remains unelucidated. METHODS By using single-cell RNA sequencing (scRNA-seq), we aimed to define a proper taxonomy for native human BM non-hematopoietic subsets including endothelial cells (ECs) and mural cells (MCs) but with a focal point on MSCs. To this end, transcriptomic scRNA-seq data were generated from 5 distinct BM donors and were analyzed together with other transcriptomic data and with computational biology analyses at different levels to identify, characterize and classify distinct native cell subsets with relevant biomarkers. RESULTS We could ascribe novel specific biomarkers to ECs, MCs and MSCs. Unlike ECs and MCs, MSCs exhibited an adipogenic transcriptomic pattern while co-expressing genes related to hematopoiesis support and multilineage commitment potential. Furthermore, by a comparative analysis of scRNA-seq of BM cells from humans and mice, we identified core genes conserved in both species. Notably, we identified MARCKS, CXCL12, PDGFRA, and LEPR together with adipogenic factors as archetypal biomarkers of native MSCs within BM. In addition, our data suggest some complex gene nodes regulating critical biological functions of native BM-MSCs together with a preferential commitment toward an adipocyte lineage. CONCLUSIONS Overall, our taxonomy for native BM non-hematopoietic compartment provides an explicit depiction of gene expression in human ECs, MCs and MSCs at single-cell resolution. This analysis helps enhance our understanding of the phenotype and the complexity of biological functions of native human BM-MSCs.
Collapse
Affiliation(s)
- Loïc Fiévet
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
- CHU de Toulouse, IFB, Hôpital Purpan, Toulouse, France
| | - Nicolas Espagnolle
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
| | - Daniela Gerovska
- Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, 20014, San Sebastián, Spain
- Basque Foundation for Science, IKERBASQUE, 48009, Bilbao, Spain
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940, Leioa, Spain
| | - David Bernard
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
| | - Charlotte Syrykh
- Department d'Anatomie Pathologique, Institut Universitaire du Cancer, CHU de Toulouse, Toulouse, France
| | - Camille Laurent
- Department d'Anatomie Pathologique, Institut Universitaire du Cancer, CHU de Toulouse, Toulouse, France
| | - Pierre Layrolle
- Tonic Inserm/UPS UMR 1214, CHU Purpan Hospital, Toulouse, France
- UMR 1238 Inserm, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, Nantes, France
| | - Julien De Lima
- UMR 1238 Inserm, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, Nantes, France
| | - Arthur Justo
- Department de Chirurgie Orthopédique, Pierre Paul Riquet, Hôpital Purpan, Toulouse, France
| | - Nicolas Reina
- Department de Chirurgie Orthopédique, Pierre Paul Riquet, Hôpital Purpan, Toulouse, France
| | - Louis Casteilla
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
| | - Marcos J Araúzo-Bravo
- Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, 20014, San Sebastián, Spain
- Basque Foundation for Science, IKERBASQUE, 48009, Bilbao, Spain
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940, Leioa, Spain
| | - Abderrahim Naji
- Department of Environmental Medicine, Cooperative Medicine Unit, Research and Education Faculty, Medicine Science Cluster, Nankoku, Kochi Prefecture, Japan
| | - Jean-Christophe Pagès
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France
- CHU de Toulouse, IFB, Hôpital Purpan, Toulouse, France
| | - Frédéric Deschaseaux
- RESTORE, Université de Toulouse, EFS Occitanie, INP-ENVT, Inserm U1301, UMR CNRS 5070, France, Université de Toulouse, Toulouse, France.
| |
Collapse
|
2
|
Han W, El Botty R, Montaudon E, Malaquin L, Deschaseaux F, Espagnolle N, Marangoni E, Cottu P, Zalcman G, Parrini MC, Assayag F, Sensebe L, Silberzan P, Vincent-Salomon A, Dutertre G, Roman-Roman S, Descroix S, Camonis J. In vitro bone metastasis dwelling in a 3D bioengineered niche. Biomaterials 2020; 269:120624. [PMID: 33421710 DOI: 10.1016/j.biomaterials.2020.120624] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 12/06/2020] [Accepted: 12/18/2020] [Indexed: 12/28/2022]
Abstract
Bone is the most frequent metastasis site for breast cancer. As well as dramatically increasing disease burden, bone metastases are also an indicator of poor prognosis. One of the main challenges in investigating bone metastasis in breast cancer is engineering in vitro models that replicate the features of in vivo bone environments. Such in vitro models ideally enable the biology of the metastatic cells to mimic their in vivo behavior as closely as possible. Here, taking benefit of cutting-edge technologies both in microfabrication and cancer cell biology, we have developed an in vitro breast cancer bone-metastasis model. To do so we first 3D printed a bone scaffold that reproduces the trabecular architecture and that can be conditioned with osteoblast-like cells, a collagen matrix, and mineralized calcium. We thus demonstrated that this device offers an adequate soil to seed primary breast cancer bone metastatic cells. In particular, patient-derived xenografts being considered as a better approach than cell lines to achieve clinically relevant results, we demonstrate the ability of this biomimetic bone niche model to host patient-derived xenografted metastatic breast cancer cells. These patient-derived xenograft cells show a long-term survival in the bone model and maintain their cycling propensity, and exhibit the same modulated drug response as in vivo. This experimental system enables access to the idiosyncratic features of the bone microenvironment and cancer bone metastasis, which has implications for drug testing.
Collapse
Affiliation(s)
- Weijing Han
- Institut Curie, Centre de Recherche, Paris Sciences et Lettres Research University, 75005, Paris, France; ART Group, Inserm U830, 75005, Paris, France; Laboratoire PhysicoChimie Curie, Institut Curie, PSL Research University - Sorbonne Université - CNRS. Equipe Labellisée Ligue Contre le Cancer; 75005, Paris, France
| | - Rania El Botty
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France
| | - Elodie Montaudon
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France
| | - Laurent Malaquin
- LAAS-CNRS, Université de Toulouse, CNRS, F-31400, Toulouse, France
| | - Frederic Deschaseaux
- STROMALab, Etablissement Français Du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, ERL5311 CNRS, National Veterinary School of Toulouse (ENVT), Toulouse, France
| | - Nicolas Espagnolle
- STROMALab, Etablissement Français Du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, ERL5311 CNRS, National Veterinary School of Toulouse (ENVT), Toulouse, France
| | - Elisabetta Marangoni
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France
| | - Paul Cottu
- Department of Medical Oncology, Institut Curie and Paris Sciences et Lettres Research University, 75005, Paris, France
| | - Gérard Zalcman
- Institut Curie, Centre de Recherche, Paris Sciences et Lettres Research University, 75005, Paris, France; ART Group, Inserm U830, 75005, Paris, France; Thoracic Oncology Department and Early Phase Unit CIC-1425, Hôpital Bichat, AP-HP, Université de Paris, 75018, Paris, France
| | - Maria Carla Parrini
- Institut Curie, Centre de Recherche, Paris Sciences et Lettres Research University, 75005, Paris, France; ART Group, Inserm U830, 75005, Paris, France
| | - Franck Assayag
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France
| | - Luc Sensebe
- STROMALab, Etablissement Français Du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, ERL5311 CNRS, National Veterinary School of Toulouse (ENVT), Toulouse, France
| | - Pascal Silberzan
- Laboratoire PhysicoChimie Curie, Institut Curie, PSL Research University - Sorbonne Université - CNRS. Equipe Labellisée Ligue Contre le Cancer; 75005, Paris, France
| | - Anne Vincent-Salomon
- Department of Pathology, Institut Curie Hospital, 26, Rue D'Ulm, F-75248, Paris, France
| | - Guillaume Dutertre
- Surgical Oncology Department, Institut Curie, PSL Research University, 75005, Paris, France
| | - Sergio Roman-Roman
- Translational Research Department, Institut Curie, PSL Research University, 75005, Paris, France
| | - Stephanie Descroix
- Laboratoire PhysicoChimie Curie, Institut Curie, PSL Research University - Sorbonne Université - CNRS. Equipe Labellisée Ligue Contre le Cancer; 75005, Paris, France.
| | - Jacques Camonis
- Institut Curie, Centre de Recherche, Paris Sciences et Lettres Research University, 75005, Paris, France; ART Group, Inserm U830, 75005, Paris, France.
| |
Collapse
|
3
|
Bosc C, Broin N, Fanjul M, Saland E, Farge T, Courdy C, Batut A, Masoud R, Larrue C, Skuli S, Espagnolle N, Pagès JC, Carrier A, Bost F, Bertrand-Michel J, Tamburini J, Récher C, Bertoli S, Mansat-De Mas V, Manenti S, Sarry JE, Joffre C. Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. Nat Commun 2020; 11:4056. [PMID: 32792483 PMCID: PMC7426880 DOI: 10.1038/s41467-020-17882-2] [Citation(s) in RCA: 84] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Accepted: 07/22/2020] [Indexed: 12/14/2022] Open
Abstract
Autophagy has been associated with oncogenesis with one of its emerging key functions being its contribution to the metabolism of tumors. Therefore, deciphering the mechanisms of how autophagy supports tumor cell metabolism is essential. Here, we demonstrate that the inhibition of autophagy induces an accumulation of lipid droplets (LD) due to a decrease in fatty acid β-oxidation, that leads to a reduction of oxidative phosphorylation (OxPHOS) in acute myeloid leukemia (AML), but not in normal cells. Thus, the autophagic process participates in lipid catabolism that supports OxPHOS in AML cells. Interestingly, the inhibition of OxPHOS leads to LD accumulation with the concomitant inhibition of autophagy. Mechanistically, we show that the disruption of mitochondria–endoplasmic reticulum (ER) contact sites (MERCs) phenocopies OxPHOS inhibition. Altogether, our data establish that mitochondria, through the regulation of MERCs, controls autophagy that, in turn finely tunes lipid degradation to fuel OxPHOS supporting proliferation and growth in leukemia. How autophagy supports tumor cell metabolism is not fully clear. Here, the authors show that autophagy regulates lipid availability to support mitochondrial oxidative metabolism through mitochondria-endoplasmic reticulum contact sites, necessary for cell proliferation in AML.
Collapse
Affiliation(s)
- Claudie Bosc
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Nicolas Broin
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Marjorie Fanjul
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Estelle Saland
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Thomas Farge
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Charly Courdy
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Aurélie Batut
- MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, F-31077, France
| | - Rawand Masoud
- Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France
| | - Clément Larrue
- Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, 1211, Geneva, Switzerland
| | - Sarah Skuli
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.,Division of Hematology and Oncology, Hospital of The University of Pennsylvania, Philadelphia, PA, USA
| | - Nicolas Espagnolle
- STROMALab, Université de Toulouse, CNRS ERL5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Jean-Christophe Pagès
- STROMALab, Université de Toulouse, CNRS ERL5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Alice Carrier
- Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France
| | - Frédéric Bost
- Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity and Diabetes, Université Nice Côte d'Azur, Inserm, Nice, France
| | - Justine Bertrand-Michel
- MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, F-31077, France
| | - Jérôme Tamburini
- Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, 1211, Geneva, Switzerland.,Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, F-75014, Paris, France
| | - Christian Récher
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.,Service d'hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Sarah Bertoli
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.,Service d'hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Véronique Mansat-De Mas
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.,Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Stéphane Manenti
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France
| | - Jean-Emmanuel Sarry
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France. .,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.
| | - Carine Joffre
- Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France. .,Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.
| |
Collapse
|
4
|
Ménard C, Dulong J, Roulois D, Hébraud B, Verdière L, Pangault C, Sibut V, Bezier I, Bescher N, Monvoisin C, Gadelorge M, Bertheuil N, Flécher E, Casteilla L, Collas P, Sensebé L, Bourin P, Espagnolle N, Tarte K. Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. Stem Cells 2019; 38:146-159. [PMID: 31502731 DOI: 10.1002/stem.3077] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 07/08/2019] [Accepted: 07/25/2019] [Indexed: 12/13/2022]
Abstract
Clinical-grade mesenchymal stromal cells (MSCs) can be expanded from bone marrow and adipose tissue to treat inflammatory diseases and degenerative disorders. However, the influence of their tissue of origin on their functional properties, including their immunosuppressive activity, remains unsolved. In this study, we produced paired bone marrow-derived mesenchymal stromal cell (BM-MSC) and adipose-derived stromal cell (ASC) batches from 14 healthy donors. We then compared them using transcriptomic, phenotypic, and functional analyses and validated our results on purified native MSCs to infer which differences were really endowed by tissue of origin. Cultured MSCs segregated together owing to their tissue of origin based on their gene expression profile analyzed using differential expression and weighted gene coexpression network analysis. This translated into distinct immune-related gene signatures, phenotypes, and functional cell interactions. Importantly, sorted native BM-MSCs and ASCs essentially displayed the same distinctive patterns than their in vitro-expanded counterparts. As a whole, ASCs exhibited an immune profile consistent with a stronger inhibition of immune response and a lower immunogenicity, supporting the use of adipose tissue as a valuable source for clinical applications.
Collapse
Affiliation(s)
- Cédric Ménard
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France.,SITI Laboratory, Etablissement Français du Sang Bretagne, CHU Rennes, Rennes, France
| | - Joëlle Dulong
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France.,SITI Laboratory, Etablissement Français du Sang Bretagne, CHU Rennes, Rennes, France
| | - David Roulois
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France
| | - Benjamin Hébraud
- STROMALab, Etablissement Français du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, National Veterinary School of Toulouse (ENVT), ERL5311 CNRS, Toulouse, France
| | - Léa Verdière
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France
| | - Céline Pangault
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France.,Pôle Biologie, CHU Rennes, Rennes, France
| | - Vonick Sibut
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France.,SITI Laboratory, Etablissement Français du Sang Bretagne, CHU Rennes, Rennes, France
| | - Isabelle Bezier
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France.,SITI Laboratory, Etablissement Français du Sang Bretagne, CHU Rennes, Rennes, France
| | - Nadège Bescher
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France.,SITI Laboratory, Etablissement Français du Sang Bretagne, CHU Rennes, Rennes, France
| | - Céline Monvoisin
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France
| | - Mélanie Gadelorge
- STROMALab, Etablissement Français du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, National Veterinary School of Toulouse (ENVT), ERL5311 CNRS, Toulouse, France
| | - Nicolas Bertheuil
- SITI Laboratory, Etablissement Français du Sang Bretagne, CHU Rennes, Rennes, France.,Department of Plastic Surgery, CHU Rennes, Rennes, France
| | - Erwan Flécher
- Department of Thoracic and Cardiac Surgery, CHU Rennes, Rennes, France
| | - Louis Casteilla
- STROMALab, Etablissement Français du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, National Veterinary School of Toulouse (ENVT), ERL5311 CNRS, Toulouse, France
| | - Philippe Collas
- Department of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Luc Sensebé
- STROMALab, Etablissement Français du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, National Veterinary School of Toulouse (ENVT), ERL5311 CNRS, Toulouse, France
| | | | - Nicolas Espagnolle
- STROMALab, Etablissement Français du Sang-Occitanie (EFS), Inserm 1031, University of Toulouse, National Veterinary School of Toulouse (ENVT), ERL5311 CNRS, Toulouse, France
| | - Karin Tarte
- UMR 1236, University of Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France.,SITI Laboratory, Etablissement Français du Sang Bretagne, CHU Rennes, Rennes, France
| |
Collapse
|
5
|
Chaput B, Laloze J, Grolleau JL, Espagnolle N, Bertheuil N, Varin A. Phenotypic Analysis of Stromal Vascular Fraction after Mechanical Shear Reveals Stress-Induced Progenitor Populations. Plast Reconstr Surg 2017; 139:1024e-1025e. [PMID: 28002249 DOI: 10.1097/prs.0000000000003202] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Benoit Chaput
- Department of Plastic, Reconstructive, and Aesthetic Surgery, and, STROMAlab, UMR5273 CNRS/UPS/EFS-INSERM U1031, Rangueil Hospital, Toulouse, France
| | - Jerome Laloze
- Department of Plastic, Reconstructive, and Aesthetic Surgery, and, STROMAlab, UMR5273 CNRS/UPS/EFS-INSERM U1031, Rangueil Hospital, Toulouse, France
| | - Jean-Louis Grolleau
- Department of Plastic, Reconstructive, and Aesthetic Surgery, Rangueil Hospital, Toulouse, France
| | - Nicolas Espagnolle
- STROMAlab, UMR5273 CNRS/UPS/EFS-INSERM U1031, Rangueil Hospital, Toulouse, France
| | - Nicolas Bertheuil
- STROMAlab, UMR5273 CNRS/UPS/EFS-INSERM U1031, Rangueil Hospital, Toulouse, France, Department of Plastic, Reconstructive, and Aesthetic Surgery, Hospital Sud, University of Rennes 1, Rennes, France, SITI Laboratory, Etablissement Français du Sang Bretagne, Rennes University Hospital, Rennes, France
| | - Audrey Varin
- Department of Plastic, Reconstructive, and Aesthetic Surgery, and, STROMAlab, UMR5273 CNRS/UPS/EFS-INSERM U1031, Rangueil Hospital, Toulouse, France
| |
Collapse
|
6
|
Gadelorge M, Bourdens M, Espagnolle N, Bardiaux C, Murrell J, Savary L, Ribaud S, Chaput B, Sensebé L. Clinical-scale expansion of adipose-derived stromal cells starting from stromal vascular fraction in a single-use bioreactor: proof of concept for autologous applications. J Tissue Eng Regen Med 2017; 12:129-141. [PMID: 27943660 DOI: 10.1002/term.2377] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 09/23/2016] [Accepted: 12/06/2016] [Indexed: 01/31/2023]
Abstract
Adipose-derived stromal cells (ASCs) are adult multipotent cells increasingly used for cell therapy due to their differentiation potential, their paracrine effect and their convenience. ASCs are currently selected from stromal vascular fractions (SVFs) of adipose tissue and expanded in 2D flasks following good manufacturing practices. This process is limited in surface area, labour-intensive and expensive, especially for autologous applications requiring selection and expansion steps for every patient. Closed and automated bioreactors offer an alternative for scalable and cost-effective production of ASCs. This study investigated a single-use stirred-tank bioreactor that can expand ASCs from SVFs on microcarriers. A preliminary microcarrier screening in static and spinner flask conditions was performed to evaluate the best candidate for adhesion, amplification and harvest. The selected microcarrier was used for process development in the bioreactor. The first experiments showed poor selectivity and growth of the ASCs from the SVF (n = 2). The process was then adjusted by two means: (1) decreasing the platelet lysate in the medium for enhancing cell adherence; and (2) adding a shear protectant (Pluronic F68). Following these modifications, we demonstrated that the number of population doublings of ASCs from SVFs was not significantly different between the bioreactor and the 2D controls (n = 3). In addition, the ASC characterization after culture showed that cells maintained their clonogenic potential, phenotype, differentiation potential and immunosuppressive capacities. This study provides the proof of concept that isolation and amplification of functional ASCs from SVFs can be performed in a stirred-tank bioreactor combined with microcarriers. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Mélanie Gadelorge
- STROMALab, Université de Toulouse, EFS, INP-ENVT, Inserm, UPS, Team 2, Toulouse, France
| | - Marion Bourdens
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Team 1, Toulouse, France
| | - Nicolas Espagnolle
- STROMALab, Université de Toulouse, EFS, INP-ENVT, Inserm, UPS, Team 2, Toulouse, France
| | - Clémence Bardiaux
- STROMALab, Université de Toulouse, EFS, INP-ENVT, Inserm, UPS, Team 2, Toulouse, France
| | - Julie Murrell
- EMD Millipore, Cell Therapy Bioprocessing, 80 Ashby Rd, Bedford, MA, 01730, USA
| | - Lenaig Savary
- Millipore S.A.S., 39 Route industrielle de la Hardt, 67120, Molsheim, France
| | - Sylvain Ribaud
- Millipore S.A.S., 39 Route industrielle de la Hardt, 67120, Molsheim, France
| | - Benoît Chaput
- STROMALab, Université de Toulouse, EFS, INP-ENVT, Inserm, UPS, Team 2, Toulouse, France.,Department of Plastic, Reconstructive and Aesthetic Surgery, Rangueil Hospital, Toulouse, France
| | - Luc Sensebé
- STROMALab, Université de Toulouse, EFS, INP-ENVT, Inserm, UPS, Team 2, Toulouse, France
| |
Collapse
|
7
|
Fievet LM, Espagnolle N, Descamps J, Sensebe L, Deschaseaux F. 3D engineering human hematopoietic niche from bone marrow mesenchymal stromal cells. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Espagnolle N, Balguerie A, Arnaud E, Sensebé L, Varin A. CD54-Mediated Interaction with Pro-inflammatory Macrophages Increases the Immunosuppressive Function of Human Mesenchymal Stromal Cells. Stem Cell Reports 2017; 8:961-976. [PMID: 28330617 PMCID: PMC5390105 DOI: 10.1016/j.stemcr.2017.02.008] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 02/09/2017] [Accepted: 02/10/2017] [Indexed: 02/08/2023] Open
Abstract
Mesenchymal stromal cells (MSCs) sense and modulate inflammation and represent potential clinical treatment for immune disorders. However, many details of the bidirectional interaction of MSCs and the innate immune compartment are still unsolved. Here we describe an unconventional but functional interaction between pro-inflammatory classically activated macrophages (M1MΦ) and MSCs, with CD54 playing a central role. CD54 was upregulated and enriched specifically at the contact area between M1MФ and MSCs. Moreover, the specific interaction induced calcium signaling and increased the immunosuppressive capacities of MSCs dependent on CD54 mediation. Our data demonstrate that MSCs can detect an inflammatory microenvironment via a direct and physical interaction with innate immune cells. This finding opens different perspectives for MSC-based cell therapy. Unconventional but functional interaction between M1MФ and MSCs CD54-dependent M1MФ-MSC interaction increases MSC immunosuppressive properties First characterization of physical interaction between stromal cells and MΦ
Collapse
Affiliation(s)
- Nicolas Espagnolle
- STROMALab (Team 2), Université de Toulouse, EFS, INP-ENVT, INSERM U1031, UPS, 31042 Toulouse, France; EFS Pyrénées-Méditerranée, 31042 Toulouse, France
| | - Adélie Balguerie
- STROMALab (Team 2), Université de Toulouse, EFS, INP-ENVT, INSERM U1031, UPS, 31042 Toulouse, France; EFS Pyrénées-Méditerranée, 31042 Toulouse, France
| | - Emmanuelle Arnaud
- STROMALab (Team 1), Université de Toulouse, CNRS ERL5311, EFS, INP-ENVT, INSERM U1031, UPS, 31042 Toulouse, France
| | - Luc Sensebé
- STROMALab (Team 2), Université de Toulouse, EFS, INP-ENVT, INSERM U1031, UPS, 31042 Toulouse, France; EFS Pyrénées-Méditerranée, 31042 Toulouse, France.
| | - Audrey Varin
- STROMALab (Team 2), Université de Toulouse, EFS, INP-ENVT, INSERM U1031, UPS, 31042 Toulouse, France; EFS Pyrénées-Méditerranée, 31042 Toulouse, France.
| |
Collapse
|
9
|
Naji A, Suganuma N, Espagnolle N, Yagyu K, Baba N, Sensebé L, Deschaseaux F. Rationale for Determining the Functional Potency of Mesenchymal Stem Cells in Preventing Regulated Cell Death for Therapeutic Use. Stem Cells Transl Med 2016; 6:713-719. [PMID: 28297565 PMCID: PMC5442793 DOI: 10.5966/sctm.2016-0289] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Accepted: 09/19/2016] [Indexed: 12/19/2022] Open
Abstract
Mesenchymal stem (stromal) cells (MSCs) are being investigated for treating degenerative and inflammatory disorders because of their reparative and immunomodulatory properties. Intricate mechanisms relate cell death processes with immune responses, which have implications for degenerative and inflammatory conditions. We review the therapeutic value of MSCs in terms of preventing regulated cell death (RCD). When cells identify an insult, specific intracellular pathways are elicited for execution of RCD processes, such as apoptosis, necroptosis, and pyroptosis. To some extent, exacerbated RCD can provoke an intense inflammatory response and vice versa. Emerging studies are focusing on the molecular mechanisms deployed by MSCs to ameliorate the survival, bioenergetics, and functions of unfit immune or nonimmune cells. Given these aspects, and in light of MSC actions in modulating cell death processes, we suggest the use of novel functional in vitro assays to ensure the potency of MSCs for preventing RCD. Such analyses should be associated with existing functional assays measuring the anti‐inflammatory capabilities of MSCs in vitro. MSCs selected on the basis of two in vitro functional criteria (i.e., prevention of inflammation and RCD) could possess optimal therapeutic efficacy in vivo. In addition, we underline the implications of these perspectives in clinical studies of MSC therapy, with particular focus on acute respiratory distress syndrome. Stem Cells Translational Medicine2017;6:713–719
Collapse
Affiliation(s)
- Abderrahim Naji
- Center for Innovative and Translational Medicine, Kochi Medical School, Kochi University, Kochi, Japan
- Department of Environmental Medicine, Kochi Medical School, Kochi University, Kochi, Japan
| | - Narufumi Suganuma
- Center for Innovative and Translational Medicine, Kochi Medical School, Kochi University, Kochi, Japan
- Department of Environmental Medicine, Kochi Medical School, Kochi University, Kochi, Japan
| | - Nicolas Espagnolle
- STROMALab, INSERM U1031, EFS Pyrénées‐Méditerranée, Université de Toulouse, Toulouse, France
| | - Ken‐ichi Yagyu
- Science Research Center, Division of Biological Research, Life Sciences and Functional Materials, Kochi Medical School, Kochi University, Kochi, Japan
| | - Nobuyasu Baba
- Center for Innovative and Translational Medicine, Kochi Medical School, Kochi University, Kochi, Japan
| | - Luc Sensebé
- STROMALab, INSERM U1031, EFS Pyrénées‐Méditerranée, Université de Toulouse, Toulouse, France
| | - Frédéric Deschaseaux
- STROMALab, INSERM U1031, EFS Pyrénées‐Méditerranée, Université de Toulouse, Toulouse, France
| |
Collapse
|
10
|
Gadelorge M, Bourdens M, Bardiaux C, Espagnolle N, Murrell J, Savary L, Ribaud S, Chaput B, Sensebé L. Expansion of Adipose Derived Stromal Cells from Stromal Vascular Fraction in a Single-Use Bioreactor: Proof of Concept in the Mobius® 3L. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Espagnolle N, Barron P, Mandron M, Blanc I, Bonnin J, Agnel M, Kerbelec E, Herault JP, Savi P, Bono F, Alam A. Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells. Cancers (Basel) 2014; 6:472-90. [PMID: 24589997 PMCID: PMC3980599 DOI: 10.3390/cancers6010472] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Revised: 02/06/2014] [Accepted: 02/17/2014] [Indexed: 12/16/2022] Open
Abstract
Myeloid derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) represent prominent components in cancer progression. We previously showed that inhibition of the VEGFR-3 pathway by SAR131675 leads to reduction of TAM infiltration and tumor growth. Here, we found that treatment with SAR131675 prevents the accumulation of immunosuppressive blood and splenic MDSCs which express VEGFR-3, in 4T1 tumor bearing mice. Moreover we showed that soluble factors secreted by tumor cells promote MDSCs proliferation and differentiation into M2 polarized F4/80+ macrophages. In addition, cell sorting and transcriptomic analysis of tumor infiltrating myeloid cells revealed the presence of a heterogeneous population that could be divided into 3 subpopulations: (i) immature cells with a MDSC phenotype (GR1+/CD11b+/F4/80−); (ii) “immuno-incompetent” macrophages (F4/80high/CD86neg/MHCIILow) strongly expressing M2 markers such as Legumain, CD206 and Mgl1/2 and (iii) “immuno-competent”-M1 like macrophages (F4/80Low/CD86+/MHCIIHigh). SAR131675 treatment reduced MDSCs in lymphoid organs as well as F4/80High populations in tumors. Interestingly, in the tumor SAR131675 was able to increase the immunocompetent M1 like population (F4/80low). Altogether these results demonstrate that the specific VEGFR-3 inhibitor SAR131675 exerts its anti tumoral activity by acting on different players that orchestrate immunosuppression and cancer progression in a tumoral context: MDSCs in peripheral lymphoid organs and TAMs infiltrating the tumor.
Collapse
Affiliation(s)
| | - Pauline Barron
- Sanofi Recherche et Développement, Early to Candidate DPU, Toulouse 31036, France.
| | - Marie Mandron
- Sanofi Recherche et Développement, Early to Candidate DPU, Toulouse 31036, France.
| | - Isabelle Blanc
- Sanofi Recherche et Développement, Early to Candidate DPU, Toulouse 31036, France.
| | - Jacques Bonnin
- Sanofi Recherche et Développement, Early to Candidate DPU, Toulouse 31036, France.
| | - Magali Agnel
- Molecular Biology Unit, Biologics Department, Sanofi, Vitry-sur-Seine 94400, France.
| | - Erwan Kerbelec
- Molecular Biology Unit, Biologics Department, Sanofi, Vitry-sur-Seine 94400, France.
| | - Jean Pascal Herault
- Sanofi Recherche et Développement, Early to Candidate DPU, Toulouse 31036, France.
| | - Pierre Savi
- Sanofi Recherche et Développement, Early to Candidate DPU, Toulouse 31036, France.
| | - Françoise Bono
- Sanofi Recherche et Développement, Early to Candidate DPU, Toulouse 31036, France.
| | - Antoine Alam
- Sanofi Recherche et Développement, Early to Candidate DPU, Toulouse 31036, France.
| |
Collapse
|
12
|
Espagnolle N, Guilloton F, Deschaseaux F, Gadelorge M, Sensébé L, Bourin P. CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med 2013; 18:104-14. [PMID: 24188055 PMCID: PMC3916122 DOI: 10.1111/jcmm.12168] [Citation(s) in RCA: 100] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Accepted: 09/16/2013] [Indexed: 12/26/2022] Open
Abstract
Bone marrow mesenchymal stem cells (MSCs) are plastic adherent cells that can differentiate into various tissue lineages, including osteoblasts, adipocytes and chondrocytes. However, this progenitor property is not shared by all cells within the MSC population. In addition, MSCs vary in their proliferation capacity and expression of markers. Because of heterogeneity of CD146 expression in the MSC population, we compared CD146−/Low and CD146High cells under clonal conditions and after sorting of the non-clonal cell population to determine whether this expression is associated with specific functions. CD146−/Low and CD146High bone marrow MSCs did not differ in colony-forming unit-fibroblast number, osteogenic, adipogenic and chondrogenic differentiation or in vitro haematopoietic-supportive activity. However, CD146−/Low clones proliferated slightly but significantly faster than did CD146High clones. In addition, a strong expression of CD146 molecule was associated with a commitment to a vascular smooth muscle cell (VSMC) lineage characterized by a strong up-regulation of calponin-1 and SM22α expression and an ability to contract collagen matrix. Thus, within a bone marrow MSC population, certain subpopulations characterized by high expression of CD146, are committed towards a VSMC lineage.
Collapse
Affiliation(s)
- Nicolas Espagnolle
- EFS Pyrénées Méditerranée UMR5273 CNRS/UPS/EFS, Inserm U1031 STROMALab, Toulouse, France
| | | | | | | | | | | |
Collapse
|
13
|
Bouacida A, Rosset P, Trichet V, Guilloton F, Espagnolle N, Cordonier T, Heymann D, Layrolle P, Sensébé L, Deschaseaux F. Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. PLoS One 2012; 7:e48648. [PMID: 23144918 PMCID: PMC3492496 DOI: 10.1371/journal.pone.0048648] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Accepted: 09/27/2012] [Indexed: 01/18/2023] Open
Abstract
Mesenchymal stem cells (MSCs) and pericyte progenitors (PPs) are both perivascular cells with similar multipotential properties regardless of tissue of origin. We compared the phenotype and function of the 2 cell types derived from the same bone-marrow samples but expanded in their respective media - pericyte conditions (endothelial cell growth medium 2 [EGM-2]) for PPs and standard medium (mesenchymal stem cell medium [MSM]) for MSCs. After 3 weeks of culture, whatever the expansion medium, all cells showed similar characteristics (MSC markers and adipo-osteo-chondroblastic differentiation potential), although neuronal potential was greater in EGM-2- than MSM-cultured cells. As compared with MSM-cultured MSCs, EGM-2-cultured PPs showed higher expression of the pericyte-specific antigen 3G5 than α-smooth muscle actin. In addition, EGM-2-cultured PPs showed an immature phenotype, with upregulation of stemness OCT4 and SOX2 proteins and downregulation of markers of osteoblastic, chondroblastic, adipocytic and vascular smooth muscle lineages. Despite having less effective in vitro immunosuppression capacities than standard MSCs, EGM-2-cultured PPs had higher engraftment potentials when combined with biomaterials heterotopically-transplanted in Nude mice. Furthermore, these engrafted cells generated more collagen matrix and were preferentially perivascular or lined trabeculae as compared with MSM-cultured MSCs. In conclusion, EGM-2-cultured PPs are highly immature cells with increased plasticity and engraftment potential.
Collapse
Affiliation(s)
- Amina Bouacida
- Stromalab Unité Mixte de Recherche (UMR) Université Paul Sabatier/Centre National de la Recherche Scientifique (CNRS) 5273, U1031 Institut national de la santé et de la recherche médicale (Inserm), Etablissement Français du Sang-Pyrénées-Méditerranée, Toulouse, France
- EA3855, Université François Rabelais, Tours, France
| | - Philippe Rosset
- Inserm UMR957, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes, Nantes, France
- Centre Hospitalier Universitaire Trousseau, Tours, France
| | - Valérie Trichet
- Inserm UMR957, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes, Nantes, France
| | - Fabien Guilloton
- Stromalab Unité Mixte de Recherche (UMR) Université Paul Sabatier/Centre National de la Recherche Scientifique (CNRS) 5273, U1031 Institut national de la santé et de la recherche médicale (Inserm), Etablissement Français du Sang-Pyrénées-Méditerranée, Toulouse, France
| | - Nicolas Espagnolle
- Stromalab Unité Mixte de Recherche (UMR) Université Paul Sabatier/Centre National de la Recherche Scientifique (CNRS) 5273, U1031 Institut national de la santé et de la recherche médicale (Inserm), Etablissement Français du Sang-Pyrénées-Méditerranée, Toulouse, France
| | - Thomas Cordonier
- Inserm UMR957, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes, Nantes, France
| | - Dominique Heymann
- Inserm UMR957, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes, Nantes, France
| | - Pierre Layrolle
- Inserm UMR957, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes, Nantes, France
| | - Luc Sensébé
- Stromalab Unité Mixte de Recherche (UMR) Université Paul Sabatier/Centre National de la Recherche Scientifique (CNRS) 5273, U1031 Institut national de la santé et de la recherche médicale (Inserm), Etablissement Français du Sang-Pyrénées-Méditerranée, Toulouse, France
| | - Frédéric Deschaseaux
- Stromalab Unité Mixte de Recherche (UMR) Université Paul Sabatier/Centre National de la Recherche Scientifique (CNRS) 5273, U1031 Institut national de la santé et de la recherche médicale (Inserm), Etablissement Français du Sang-Pyrénées-Méditerranée, Toulouse, France
- * E-mail:
| |
Collapse
|
14
|
Carreño L, Riquelme E, González P, Espagnolle N, Riedel C, Valitutti S, Kalergis A. A novel form of T cell antagonism by trapping of immunological synapse (106.49). The Journal of Immunology 2012. [DOI: 10.4049/jimmunol.188.supp.106.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
T cell activation results from productive T cell receptor (TCR) engagement by a cognate peptide-MHC (pMHC) complex on the antigen presenting cell (APC) surface, a process leading to the polarization of the T cell secretory machinery towards the interface of APC. We have previously shown that the half-life of the TCR/pMHC interaction and the density of pMHC on the APC are two parameters determining T cell activation. Here, by using APLs conferring different half-lives to the TCR/pMHC interaction we have tested how this parameter can control T cell polarization. We observed that only TCR/pMHC interactions with intermediate half-lives can promote the assembly of synapses that lead to T cell activation. Strikingly, intermediate half-life interactions can be competed out by short half-life interactions, which can efficiently promote T cell polarization and antagonize T cell activation that was induced by activating intermediate half-life interactions. However, short TCR/pMHC interactions fail at promoting phosphorylation of signaling molecules at the T cell-APC contact interface, which are needed for T cell activation. Our data suggest that while intermediate half-life pMHC ligands promote assembly of activating synapses, this process can be inhibited by short half-life antagonistic pMHC ligands, which promote the assembly of non activating synapses.
Collapse
Affiliation(s)
- Leandro Carreño
- 1Genetica Molecular y Microbiologia, Universidad Catolica de Chile, Santiago, Chile
| | - Erick Riquelme
- 1Genetica Molecular y Microbiologia, Universidad Catolica de Chile, Santiago, Chile
| | - Pablo González
- 1Genetica Molecular y Microbiologia, Universidad Catolica de Chile, Santiago, Chile
| | | | - Claudia Riedel
- 3Facultad de Ciencias Biológicas and Facultad de Medicina, Universidad Andrés Bello, Santiago, Chile
| | | | - Alexis Kalergis
- 1Genetica Molecular y Microbiologia, Universidad Catolica de Chile, Santiago, Chile
| |
Collapse
|
15
|
Corre J, Labat E, Espagnolle N, Hébraud B, Avet-Loiseau H, Roussel M, Huynh A, Gadelorge M, Cordelier P, Klein B, Moreau P, Facon T, Fournié JJ, Attal M, Bourin P. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res 2012; 72:1395-406. [PMID: 22301101 DOI: 10.1158/0008-5472.can-11-0188] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Overexpression of growth differentiation factor 15 (GDF15) by bone marrow mesenchymal stem cells occurs widely in patients with multiple myeloma, but the pathophysiologic effects of GDF15 in this setting remain undefined. GDF15 has been described in numerous solid tumors but never in hematologic malignancies. In this study, we report that GDF15 significantly increases survival of stroma-dependent multiple myeloma cells including primary multiple myeloma cells. In particular, GDF15 conferred resistance to melphalan, bortezomib, and to a lesser extent, lenalidomide in both stroma-dependent and stroma-independent multiple myeloma cells. Akt-dependent signaling was critical to mediate the effects of GDF15, whereas Src and extracellular signal-regulated kinase 1/2 signaling pathways were not involved. Given these results, we tested the clinical significance of plasma concentrations of GDF15 (pGDF15) in 131 patients with multiple myeloma and found that it correlated with disease prognosis. Specifically, patients with high levels of pGDF15 had lower probabilities of event-free and overall survival 30 months after diagnosis than patients with low pGDF15 levels. Our findings suggest that tumor microenvironment-derived GDF15 is a key survival and chemoprotective factor for multiple myeloma cells, which is pathophysiologically linked to both initial parameters of the disease as well as patient survival.
Collapse
Affiliation(s)
- Jill Corre
- Institut National de la Santé et de la Recherche Médicale, U1037, Toulouse, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Carreño LJ, Riquelme EM, González PA, Espagnolle N, Riedel CA, Valitutti S, Kalergis AM. T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC. Proc Natl Acad Sci U S A 2010; 107:210-5. [PMID: 20075022 PMCID: PMC2806700 DOI: 10.1073/pnas.0911258107] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
T-cell activation results from productive T-cell receptor (TCR) engagement by a cognate peptide-MHC (pMHC) complex on the antigen presenting cell (APC) surface, a process leading to the polarization of the T-cell secretory machinery toward the APC interface. We have previously shown that the half-life of the TCR/pMHC interaction and the density of pMHC on the APC are two parameters determining T-cell activation. However, whether the half-life of the TCR/pMHC interaction can modulate the efficiency of T-cell secretory machinery polarization toward an APC still remains unclear. Here, by using altered peptide ligands conferring different half-lives to the TCR/pMHC interaction, we have tested how this parameter can control T-cell polarization. We observed that only TCR/pMHC interactions with intermediate half-lives can promote the assembly of synapses that lead to T-cell activation. Strikingly, intermediate half-life interactions can be competed out by short half-life interactions, which can efficiently promote T-cell polarization and antagonize T-cell activation that was induced by activating intermediate half-life interactions. However, short TCR/pMHC interactions fail at promoting phosphorylation of signaling molecules at the T-cell-APC contact interface, which are needed for T-cell activation. Our data suggest that although intermediate half-life pMHC ligands promote assembly of activating synapses, this process can be inhibited by short half-life antagonistic pMHC ligands, which promote the assembly of non activating synapses.
Collapse
Affiliation(s)
- Leandro J. Carreño
- Millennium Nucleus on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile
| | - Erick M. Riquelme
- Millennium Nucleus on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile
| | - Pablo A. González
- Millennium Nucleus on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile
| | | | - Claudia A. Riedel
- Millennium Nucleus on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile
- Facultad de Ciencias Biológicas and
- Facultad de Medicina, Universidad Andrés Bello, Santiago 8370146, Chile; and
| | | | - Alexis M. Kalergis
- Millennium Nucleus on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile
- Facultad de Medicina. Pontificia Universidad Católica de Chile, Santiago 8331010, Chile
| |
Collapse
|
17
|
Espagnolle N, Depoil D, Zaru R, Demeur C, Champagne E, Guiraud M, Valitutti S. CD2 and TCR synergize for the activation of phospholipase C 1/calcium pathway at the immunological synapse. Int Immunol 2007; 19:239-48. [PMID: 17220479 DOI: 10.1093/intimm/dxl141] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Upon conjugation with cognate antigen-presenting cells (APCs), T lymphocytes undergo a sustained [Ca(2+)](i) increase resulting from the engagement of TCR and of accessory molecules with ligands expressed on the surface of APCs. We investigated the contribution of the accessory molecule CD2 to the activation of phospholipase Cgamma1 (PLCgamma1)/calcium pathway in antigen-stimulated T cells. We show that CD2 binding with its ligand CD58 expressed on the surface of APCs augments and sustains antigen-induced [Ca(2+)](i) increase in individual T cells interacting with APCs. We also show that in conditions in which CD2-CD58 interaction is impeded, the recruitment of PLCgamma1 to the immunological synapse (IS) is reduced. Interestingly, in these conditions PLCgamma1 phosphorylation in the regulatory tyrosine 783 is also defective. Our results indicate that TCR- and CD2-derived signals converge for the recruitment and activation of PLCgamma1 at the IS and shed new light on the accessory function of CD2 in T cell activation by specific antigen.
Collapse
Affiliation(s)
- Nicolas Espagnolle
- INSERM U563, Lymphocyte Interaction Group, Institut Claude de Préval, CHU Purpan, 31059 Toulouse, France
| | | | | | | | | | | | | |
Collapse
|